TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

doi:10.4251/wjgo.v11.i7.551

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7389)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

456

WORD

263

HTML

3711

Figures (1-2)

230

Tables (1-6)

227

Sum=4887

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

923

Download

1579

Sum=2502

Jul 15, 2019 (publication date) through Sep 26, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jul 15, 2019; 11(7): 551-566
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551

Table 4 Associations between patient characteristics and TYMS polymorphisms

Patient characteristics	Polymorphisms	RR (95%CI)	P value
Birth after 1942	3RG/3RG	5.128 (1.131-23.26)	0.025
	3RC/3RC and 3RC/LOH	0.296 (0.088-0.988)	0.035
Male	3RG/3RG and 3RG/LOH	4.519 (1.072-19.06)	0.030
Grade III-IV	3RG/3RC	2.646 (1.167-6.024)	0.022
Stage III	3RG/3RG and 3RG/3RC and 3RG/LOH	2.198 (1.126-4.292)	0.020
	3RG/3RC	4.149 (1.280-13.51)	0.008
	Without any 3RG allele	0.733 (0.546-0.984)	0.050
	3RC/3RC and 3RC/LOH	0.333 (1.229-0.904)	0.030
	3RC/LOH	0.122 (0.015-0.986)	0.045
KRAS mutation	3RG/3RC	3.135 (1.344-7.299)	0.010
	3RC/3RC and 3RC/LOH	0.241 (0.057-1.015)	0.030

TYMS: Thymidylate synthase gene; RR: Relative risk; CI: Confidence interval; LOH: Loss of heterozygosity.

Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566
URL: https://www.wjgnet.com/1948-5204/full/v11/i7/551.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i7.551